MX2021010531A - Proteina de fusion bifuncional y uso farmaceutico de la misma. - Google Patents

Proteina de fusion bifuncional y uso farmaceutico de la misma.

Info

Publication number
MX2021010531A
MX2021010531A MX2021010531A MX2021010531A MX2021010531A MX 2021010531 A MX2021010531 A MX 2021010531A MX 2021010531 A MX2021010531 A MX 2021010531A MX 2021010531 A MX2021010531 A MX 2021010531A MX 2021010531 A MX2021010531 A MX 2021010531A
Authority
MX
Mexico
Prior art keywords
fusion protein
bifunctional fusion
pharmaceutical use
sirpî3
bifunctional
Prior art date
Application number
MX2021010531A
Other languages
English (en)
Inventor
Xin Ye
Weikang Tao
Hu Ge
Xiaoling Gu
Bing Hu
Original Assignee
Jiangsu Hengrui Medicine Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co filed Critical Jiangsu Hengrui Medicine Co
Publication of MX2021010531A publication Critical patent/MX2021010531A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/812—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/82—Colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Abstract

Se proporcionan una proteína de fusión bifuncional y su uso farmacéutico. Específicamente, se proporciona una proteína de fusión bifuncional que comprende una variante del péptido SIRP? y un anticuerpo anti-PD-L1 humano, una variante del péptido SIRP? y su uso farmacéutico. La proteína de fusión bifuncional puede unirse específicamente a PD-L1 y CD47 para bloquear la unión de PD-L1 o CD47 a un receptor o ligando del mismo. Además, también se proporcionan la preparación y aplicación de la proteína de fusión bifuncional y el tratamiento de cánceres y enfermedades relacionadas con el sistema inmunológico.
MX2021010531A 2019-03-06 2020-03-05 Proteina de fusion bifuncional y uso farmaceutico de la misma. MX2021010531A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910168433 2019-03-06
CN201910437477 2019-05-24
PCT/CN2020/077907 WO2020177733A1 (zh) 2019-03-06 2020-03-05 双功能融合蛋白及其医药用途

Publications (1)

Publication Number Publication Date
MX2021010531A true MX2021010531A (es) 2021-10-01

Family

ID=72337007

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021010531A MX2021010531A (es) 2019-03-06 2020-03-05 Proteina de fusion bifuncional y uso farmaceutico de la misma.

Country Status (11)

Country Link
US (1) US20230012428A1 (es)
EP (1) EP3936526A4 (es)
JP (1) JP2022523543A (es)
KR (1) KR20210137477A (es)
CN (2) CN116239698A (es)
AU (1) AU2020233058A1 (es)
BR (1) BR112021017399A2 (es)
CA (1) CA3132078A1 (es)
MX (1) MX2021010531A (es)
TW (1) TW202100562A (es)
WO (1) WO2020177733A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6983371B2 (ja) * 2015-11-17 2021-12-17 スーヂョウ サンケイディア バイオファーマスーティカルズ カンパニー リミテッド 抗ｐｄ−ｌ１抗体、その抗原結合フラグメントおよびその医療用途
JP2021534769A (ja) * 2018-08-31 2021-12-16 エーエルエックス オンコロジー インコーポレイテッド デコイポリペプチド
TW202241513A (zh) * 2021-04-21 2022-11-01 大陸商江蘇恆瑞醫藥股份有限公司 一種包含抗體融合蛋白的醫藥組成物及其用途
AU2022273737A1 (en) 2021-05-14 2023-11-16 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Antigen-binding molecule
CN113321735B (zh) * 2021-05-20 2023-01-06 盛禾(中国)生物制药有限公司 一种多功能融合蛋白
CN117480180A (zh) 2021-07-14 2024-01-30 江苏恒瑞医药股份有限公司 特异性结合hgfr和egfr的抗原结合分子及其医药用途
CN113773401B (zh) * 2021-09-15 2023-06-20 宜明昂科生物医药技术（上海）股份有限公司 靶向cd47和pd-l1的重组融合蛋白及其制备和用途
WO2023183892A1 (en) * 2022-03-24 2023-09-28 Bitterroot Bio, Inc. Sirp-alpha fusion polypeptides with modified fc domains
CN116987198B (zh) * 2023-09-28 2023-12-26 军科正源（北京）药物研究有限责任公司 一种靶向人pd-l1的融合蛋白及其用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
DK3789038T3 (da) 2010-05-14 2022-10-17 Univ Leland Stanford Junior Humaniserede og kimære monoklonale antistoffer mod cd47
EP2925782B1 (en) 2012-12-03 2020-01-22 NovImmune SA Anti-cd47 antibodies and methods of use thereof
SG11201504469XA (en) 2012-12-12 2015-07-30 Vasculox Inc Therapeutic cd47 antibodies
WO2014094122A1 (en) 2012-12-17 2014-06-26 Trillium Therapeutics Inc. Treatment of cd47+ disease cells with sirp alpha-fc fusions
CN106535914B (zh) 2014-08-08 2021-08-27 Alx 肿瘤生物技术公司 SIRP-α变体构建体及其用途
WO2016023001A1 (en) 2014-08-08 2016-02-11 The Board Of Trustees Of The Leland Stanford Junior University Multispecific high affinity pd-1 agents and methods of use
CN107108748A (zh) * 2014-08-15 2017-08-29 默克专利有限公司 SIRPα免疫球蛋白融合蛋白
ES2822228T3 (es) 2014-10-24 2021-04-29 Univ Leland Stanford Junior Composiciones y métodos para inducir la fagocitosis de células positivas de clase I de CMH y contrarrestar la resistencia a anti-CD47/SIRPA
SG11201705310TA (en) 2014-12-30 2017-07-28 Celgene Corp Anti-cd47 antibodies and uses thereof
CN106146670B (zh) * 2015-04-24 2019-01-15 宜明昂科生物医药技术（上海）有限公司 一种新的重组双功能融合蛋白及其制备和应用
CN107849143B (zh) * 2015-05-18 2021-12-10 起源生物医药公司 Sirp多肽组合物和使用方法
WO2017019767A1 (en) * 2015-07-27 2017-02-02 Myosotis, Llc Inhibition of CXCL12 in Cancer Immunotherapy
RU2740672C2 (ru) * 2015-08-07 2021-01-19 ЭйЭлЭкс Онколоджи Инк. Конструкции, имеющие sirp-альфа домен или его вариант
JP6983371B2 (ja) 2015-11-17 2021-12-17 スーヂョウ サンケイディア バイオファーマスーティカルズ カンパニー リミテッド 抗ｐｄ−ｌ１抗体、その抗原結合フラグメントおよびその医療用途
CN107459578B (zh) 2016-05-31 2021-11-26 泰州迈博太科药业有限公司 一种靶向cd47与pd-l1的双功能融合蛋白
WO2018012952A1 (ko) * 2016-07-15 2018-01-18 한국과학기술연구원 신규 나노케이지 및 그의 용도
CN108779179B (zh) 2016-11-28 2022-02-08 江苏恒瑞医药股份有限公司 Cd47抗体、其抗原结合片段及其医药用途
WO2018205936A1 (zh) * 2017-05-08 2018-11-15 上海津曼特生物科技有限公司 双特异性重组蛋白及其应用

Also Published As

Publication number Publication date
WO2020177733A1 (zh) 2020-09-10
CN112969719B (zh) 2022-11-22
AU2020233058A1 (en) 2021-09-30
EP3936526A1 (en) 2022-01-12
US20230012428A1 (en) 2023-01-12
CN116239698A (zh) 2023-06-09
BR112021017399A2 (pt) 2021-11-16
KR20210137477A (ko) 2021-11-17
EP3936526A4 (en) 2023-03-08
TW202100562A (zh) 2021-01-01
CN112969719A (zh) 2021-06-15
JP2022523543A (ja) 2022-04-25
CA3132078A1 (en) 2020-09-10

Similar Documents

Publication Publication Date Title
MX2021010531A (es) Proteina de fusion bifuncional y uso farmaceutico de la misma.
WO2018057735A8 (en) Antibodies for siglec-15 and methods of use thereof
WO2020077276A3 (en) Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof
WO2016187508A3 (en) Shared neoantigens
MX2019004692A (es) Anticuerpos 4-1bb anti-humano y usos de los mismos.
MX2019013998A (es) Una proteína que se une al receptor nkg2d, al antígeno de cúmulo de diferenciación 16 (cd16) y receptores huérfanos tipo tirosina quinasa 1 o 2 (ror1 o ror2).
MX2020008333A (es) Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales.
EP4321171A3 (en) Sirp alpha-antibody fusion proteins
MX357231B (es) Polipeptidos de anticuerpos que antagonizan el ligando cd40 (cd40l).
IN2015DN02349A (es)
PT1383785E (pt) Anticorpo recombinante específico de tumores e utilização deste
WO2005012493A3 (en) Anti-cd19 antibodies
MX2021004779A (es) Anticuerpos cd47 novedosos y metodos para usarlos.
WO2019060750A3 (en) A33 antibody compositions and methods of using the same in radioimmunotherapy
MX2009009926A (es) Anticuerpo tumor-especifico humano monoclonal.
MX2020005193A (es) Fusiones de anticuerpo anti-pd-l1 e il-7.
MX2022000325A (es) Anticuerpos dirigidos contra dll3 y usos de los mismos.
WO2017124001A3 (en) T cell receptor-like antibodies specific for foxp3-derived peptides
WO2020076977A3 (en) Dll3 single domain antibodies and therapeutic compositions thereof
WO2020247388A8 (en) Il-2alpha receptor subunit binding compounds
MX2020008730A (es) Regímenes de dosificación de anticuerpo b7-h4.
AU2002354806A1 (en) Parathyroid hormone antibodies and related methods
MX2021010877A (es) Moleculas de union a cumulo de diferenciacion 3 (cd3).
WO2010009856A3 (en) Goodpasture antigen binding protein and its detection
EP3778634A4 (en) GCGR ANTIBODY AND GLP-1 FUSION PROTEIN THEREOF, PHARMACEUTICAL COMPOSITION THEREOF AND USES THEREOF